The Sustainable Nutrition Group Ltd Overview
1A. Current entity — Elixinol Wellness Limited
| Field | Detail |
|---|---|
| Legal name | Elixinol Wellness Limited |
| Former names | Elixinol Global Limited (renamed 2022; FY2022 Annual Report notes "formerly known as Elixinol Global Limited") |
| Founding year | 2017 (company incorporation; per StockAnalysis company profile) |
| Incorporation jurisdiction | Australia (public company limited by shares) |
| ACN / ABN | ACN 621 479 794 / ABN 34 621 479 794 |
| Headquarters | Suite 2, Level 11, 385 Bourke Street, Melbourne VIC 3000 (FY25 results release, 27 Feb 2026). Earlier address: Level 4, 100 Albert Road, South Melbourne VIC 3205 (Q3 FY24 4C, Oct 2024) |
| Stock exchange / tickers | ASX: EXL; US OTC: ELLXF |
| ISIN / CUSIP | — |
| Fiscal year end | 31 December |
| Employees | Not publicly disclosed in sources reviewed (3-year trend not available) |
| Auditor | FY25 financial statements received an unmodified audit opinion (TipRanks summary of FY25 Appendix 4E) |
| Share price | A$0.007 (16 October 2026 close, StockAnalysis); A$0.006 intraday 13 October 2026 (Kalkine) |
| Shares outstanding | 413.99 million (31 Dec 2025 and 30 Jun 2026; S&P Global via StockAnalysis) |
| Market capitalisation | ~A$2.9 million (StockAnalysis, latest); multiples.vc cites ~US$2 million (Oct 2026) |
| FY25 revenue | A$15.5 million (+3.6% YoY) |
| FY25 net loss after tax | A$5.5 million |
| Cash at 30 Jun 2026 | A$0.996 million |
| Website | www.elixinolwellness.com; investor hub investorhub.elixinolwellness.com |
| Chair | Gavin Evans (independent non-executive, appointed December 2025) |
| CEO | Natalie Butler (CEO & Executive Director) |
| CFO | Adam Dimitropoulos |
1B. Historical entity — The Sustainable Nutrition Group Ltd (as last reported)
| Field | Detail |
|---|---|
| Legal name | The Sustainable Nutrition Group Limited |
| Former names | Alchemia Limited (to Oct 2019); Australian Primary Hemp Limited (Oct 2019 – Oct 2021) |
| ABN | 43 071 666 334 |
| Incorporation | Australia, 1995 (as Alchemia) |
| Registered office | Level 4, 100 Albert Road, South Melbourne VIC 3205 |
| Principal place of business | 53 Riversdale Road, Newtown VIC 3220 (Geelong) |
| Former ASX codes | ACL → APH → TSN |
| Fiscal year end | 30 June |
| Auditor | William Buck Audit (Vic) Pty Ltd (H1 FY23 review report) |
| Company secretary | Melanie Leydin |
| Share registry | Link Market Services |
| Shares on issue at 31 Dec 2022 | 120,606,385 ordinary shares |
| Last market cap (aggregator) | ~A$1.41 million (MarketBeat/iocharts, stale data) |
| Website (last) | www.sustainablenutrition.com.au |
| Subsidiaries at 31 Dec 2022 | Alchemia Oncology Pty Ltd; The Sustainable Nutrition Group (Australia) Pty Ltd (formerly Australian Primary Hemp Pty Ltd); The Australian Superfood Co. — each 100% owned |
1C. Positioning statement
Elixinol Wellness is a micro-cap Australian health-and-wellness consumer goods group that, through a 2023 merger with The Sustainable Nutrition Group (formerly Australian Primary Hemp), assembled one of Australia's larger domestic hemp-food supply chains alongside a portfolio of branded nutrition products. Its brands span hemp foods (Hemp Foods Australia, Australian Primary Hemp), better-for-you grocery snacks (Mt Elephant), native superfood ingredients (The Australian Superfood Co), premium protein and wellness powders sold mainly online (The Healthy Chef), and bulk hemp ingredients supplied under contract to two major grocery programs. Having exited its US CBD business in September 2026, the company is repositioning as a purely Australian "everyday wellness" platform and has agreed to acquire Vitable, a personalised-supplement subscription business, which would lift annual revenue above A$20 million. The investment case rests on margin expansion (gross margin ~45% in 1H FY26), cost discipline and accretive roll-up M&A, against a fragile balance sheet, heavy dilution and a long record of losses.
2A. Company's own description
In its FY25 results release (27 February 2026), EXL describes itself as a health and wellness company that innovates, markets and sells hemp and other plant-derived food, skincare and nutraceutical products, operating a vertically integrated business that produces, manufactures and distributes products across nutrition, wellness and superfood-ingredient verticals, sold under Hemp Foods Australia, The Healthy Chef, Mt Elephant and The Australian Superfood Co through grocery, wholesale and e-commerce channels. Following the September 2026 US divestment, its boilerplate was updated to describe a sustainable nutrition and wellness company operating in Australia with a vertically integrated healthy-food business (ASX announcement, 7 September 2026).
TSN's last self-description (H1 FY23 interim report, 27 February 2023) characterised it as a vertically integrated producer, manufacturer and distributor of sustainable, plant-based nutrition brands — hemp products under Mt Elephant, Australian Primary Hemp, Australian Superfoods and Field Day — sold to retail, wholesale, e-commerce and white-label customers in Australia, with activities spanning seed selection, farming, processing, packaging, distribution and sales of bulk, food-service and retail products.
2B. Business model and value-chain position
The legacy APH model was "paddock-to-plate": APH purchased hemp cultivation seed, supplied it to a contracted grower network, bought back harvested grain under contract, and processed it (de-hulling, cold pressing, milling) in its own facility before selling bulk ingredients, white-label packs and branded retail products (SmallCaps, Oct 2019; Alchemia prospectus as reported). It did not breed seed itself but sourced genetics through a network that included prominent plant breeders (Stockhead, 2019). This structure created working-capital intensity — TSN carried A$3.28 million of inventory against A$1.86 million of half-year revenue at 31 December 2022, and had outstanding grain-purchase commitments of A$0.58 million (TSN H1 FY23 interim report).
EXL today layers branded consumer businesses on that supply base:
Upstream / ingredients: hemp grain sourcing, de-hulling and processing (APH, Hemp Foods Australia, Ananda Food assets acquired 2024); bulk supply contracts with two major grocery retailers' programs running to 2027 (Food & Drink Business; Grafa, Oct 2026).
Contract manufacturing and white label: supply to grocery private-label and food, beverage and beauty manufacturers (StockAnalysis profile).
Branded retail: Hemp Foods Australia, Mt Elephant (Coles-only from 2026), The Healthy Chef (e-commerce plus a ~410-store Priceline rollout).
Direct-to-consumer: The Healthy Chef e-commerce (A$4.3 million revenue in FY25) and, if approved, Vitable subscriptions.
2C. Revenue model mix
| Channel mix (Australia unless noted) | FY24 | FY25 |
|---|---|---|
| E-commerce revenue (AUD M) | 1.6 | 4.3 |
| Retail channel revenue (AUD M) | 8.8 | 7.1 |
| E-commerce share of group revenue (%) | 21 | 38 |
| Bulk ingredients share of group revenue (%) | 24 | 14 |
Source: EXL FY25 results release (27 Feb 2026) and Q4 FY25 earnings call (CFO commentary, 11–12 Feb 2026). Revenue is overwhelmingly product sales recognised at a point in time; there is no material service, licensing or subscription revenue today. The pending Vitable acquisition would introduce subscription revenue for the first time.
2D. Customer types and end-markets
Customer types: major supermarket chains (Coles; Woolworths until end-2025 for Mt Elephant), pharmacy (Priceline), club retail (Costco — Hemp Gold Protein, returning Q4 2026), convenience (7-Eleven historically), health-food independents, food manufacturers buying bulk ingredients, private-label grocery programs, and online consumers. End-markets: plant-based foods, sports and protein nutrition, functional beverages (protein water), women's health (menopause product), superfood ingredients, pet and equine nutrition (Field Day, Ananda Equine), and — until September 2026 — US CBD nutraceuticals.
Customer concentration was a defining TSN risk: four customers accounted for 60.2% of TSN external revenue in H1 FY22, falling to 34.1% in H1 FY23 after the loss of a key strategic supply agreement (TSN H1 FY23 interim report, Note 3).
2E. Independent characterisation
EXL is best understood as a sub-scale consumer packaged goods roll-up in the Australian better-for-you segment, built on the remnants of two separate hemp ventures (Elixinol's CBD business and APH's hemp food supply chain), neither of which achieved profitability independently. The group's real asset base is (i) a domestic hemp-processing capability and associated grocery supply contracts, and (ii) one genuinely high-margin brand (The Healthy Chef). Everything else is either in managed decline (Mt Elephant at Woolworths, US CBD) or low-margin bulk supply. Strategic value hinges on whether the newly assembled management team can convert gross-margin gains into sustainable positive operating cash flow before the balance sheet forces further deeply dilutive capital raising.
Strategy
10A. Stated strategy themes
Vision: build a portfolio of premium branded health-food assets with Australian manufacturing capability and global growth potential — framed as a "healthy food roll-up" (May 2026 investor presentation; FY25 release).
Positioning: a diversified health and nutrition platform built around longevity and "everyday wellness", executing against wellness megatrends such as food-first and grocery-led wellness (Q4 FY25 and May 2026 presentations). Management cites an Australian wellness market of ~A$160 billion growing to ~A$307 billion by 2033 (~7% CAGR, Global Wellness Institute data as cited by EXL).
Operating priorities for 2026: sustain positive underlying operating cash flow; grow through new retail distribution, product launches and additional B2B contracts; concentrate investment on the strongest brands (The Healthy Chef, Hemp Foods Australia); keep a lean cost base (H1 FY26 commentary).
M&A discipline: actively assess value-accretive acquisitions that use existing infrastructure and distribution or add complementary capabilities.
10B. Strategic initiatives (last 24 months)
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Healthy Chef integration and innovation | 2,025 | Six launches: menopause product, three protein waters, two limited-edition powders | Delivered |
| SKU and brand rationalisation | 2025–2026 | Exit of unprofitable products and duplicate hemp brands | Ongoing |
| Cost reset | 2,025 | Q4 FY25 cost base 30% below pcp; 1H FY26 opex down 25% | Delivered |
| Contract renegotiation | 2,025 | Legacy contracts renegotiated; expanded hemp supply contracts secured for 2026 | Delivered |
| Mt Elephant reset | End-2025 / 2026 | Exit Woolworths; Coles-only with co-developed innovation | In progress |
| Priceline rollout | 2,026 | The Healthy Chef in ~410 Priceline stores | Stage one underway |
| Costco relaunch | Q4 2026 | Hemp Gold Protein back in Costco AU/NZ | Scheduled |
| US divestment | Aug–Sep 2026 | Sale of Elixinol LLC to Ananda Health | Completed |
| Vitable acquisition | Sep 2026 | Subscription platform, cross-selling Healthy Chef into Vitable base | Pending shareholder approval |
| Capital management | 2025–2026 | A$1.5 million debt/equity (1H FY25); A$2.5 million raise (2H FY25); loan-note rollover; approval sought for up to A$2 million convertible notes (May 2026 AGM) | Ongoing |
10C. Medium-term targets
| Target | Detail | Source |
|---|---|---|
| Combined revenue after Vitable | More than A$20 million annualised from completion | EXL announcement, 24 Sep 2026 |
| 2028 target (with full earn-out) | ~A$27 million revenue and ~A$3 million EBITDA | Business News Australia; SmallCaps |
| Illustrative ambition | ~A$50 million revenue over three to five years — explicitly not formal guidance | StartupResearcher |
| Earlier target | EBITDA break-even in FY25 (stated Feb 2025) | Not achieved for the full year; Adjusted EBITDA positive in Q4 FY25 only |
Sustainability-specific commitments (emissions targets) were not disclosed.
Products & Services
5A. Australia — Hemp foods and ingredients
| Brand / product | Description and capabilities | Target customer | Launch / status | Pricing |
|---|---|---|---|---|
| Hemp Foods Australia (flagship brand) | EXL's flagship Australian hemp foods brand (Byron Bay origin): hemp seeds, protein and oil range; revenue broadly flat in 2025 vs 2024 with improving margins | Grocery, health food, online | Acquired by Elixinol pre-2020; flagship to date | — |
| Hemp Gold Protein (Hemp Foods Australia) | Hemp protein powder; ranged in Costco in 2024; returning to Costco Australia and New Zealand in Q4 2026 | Club retail shoppers | 2024 Costco; relaunch Q4 2026 | — |
| Australian Primary Hemp — hemp seeds | De-hulled Australian-grown hemp seed | Retail, bulk | Since Nov 2017 | — |
| Australian Primary Hemp — Hemp Boost / Hemp Balance | Milled hemp powders (protein; protein-plus-fibre gut-health positioning) | Health-conscious consumers | Pre-2019 | — |
| Australian Primary Hemp — cold-pressed hemp seed oil | Omega-3, 6 and 9 oil | Retail, bulk | Pre-2019 | — |
| Bulk hemp cultivation seed, hemp seed oil, protein powder, flour | Bulk ingredients and cultivation seed for growers | Food manufacturers, growers | Ongoing | Contract |
| Hemp isolate / concentrate (with Australian Plant Proteins) | Higher-protein, more soluble, lighter-flavour hemp protein designed to overcome the dark-green, ~50%-protein limitations of conventional hemp powder; allergen-friendly and non-GMO positioning; TSN to own IP with 15-year exclusivity | Food and beverage formulators, export | Stage One paid Dec 2022 | — |
| Ananda Food ingredients / Ananda Equine | Hemp ingredients for bulk, branded and private-label customers; equine products; cat litter (subject of earn-out) | Bulk buyers, equine owners, pet owners | Acquired 2024 | — |
| Grocery hemp ingredient supply | Full supply contracts for two major grocery programs through 2027 (expanded from one full and one shared arrangement in 2025) | Supermarket private-label programs | Contracts to 2027 | Contract |
5B. Australia — Branded better-for-you grocery
| Brand / product | Description | Status |
|---|---|---|
| Mt Elephant hemp seed and nut bars | Apricot & Nut, Honey & Nut, Salted Caramel; 100% Australian hemp; source of omega-3/6 and magnesium | Launched Sep 2020; 7-Eleven (720 stores) from Nov 2020 |
| Mt Elephant Mylk | Oat-and-hemp milk, Original and Chocolate; vegan, low saturated fat | Coles (140 stores) and Woolworths (165 stores) 2021; Woolworths delisted Mar 2022 |
| Mt Elephant almond and buckwheat pancakes | Vanilla and Chocolate | Coles from Jul 2021 |
| Mt Elephant superfood protein balls | Chocolate, Choc Cherry, Hazelnut | Coles from Jul 2021 |
| Mt Elephant baking products | Baking range | Woolworths from Mar 2022; exited Woolworths end-2025 |
| Mt Elephant (2026 repositioning) | Brand repositioned in 2026 and now focused exclusively on Coles, with joint innovation on flavour, format and sustainability | Coles-only from 2026 |
| Hemp and Honey Nut Bar; hemp and bush balm hand sanitiser | Legacy APH SKUs | Legacy |
5C. Australia — Superfoods, wellness and pet
| Brand / product | Description | Status |
|---|---|---|
| The Australian Superfood Co (The Super Food Co) | Australian native foods, ingredients and beverages plus nutraceutical and cosmetic ingredients; grower and Indigenous-community supply relationships; export access to South Korea and the USA | Acquired Jan 2022 (A$3 million); new opportunities progressing (FY25 release) |
| The Healthy Chef — protein powders | Premium protein and wellness powders, predominantly e-commerce; ~62% gross margin cited at acquisition (Oct 2024 investor presentation) | Acquired late 2024; core growth brand |
| The Healthy Chef — Protein Water | Functional beverage range; three new SKUs launched 2025 | Launched 2025 |
| The Healthy Chef — menopause-focused product | Women's health product | Launched 2025 |
| The Healthy Chef — limited-edition protein powders | Two limited editions | 2,025 |
| The Healthy Chef in Priceline | Stage-one rollout across ~410 Priceline pharmacies | 2,026 |
| Field Day | Pet nutrition brand (TSN legacy) | Product specifics not disclosed |
| Soul Seeds / Soul Foods | Nutrition brand listed in EXL portfolio (May 2026 presentation; StockAnalysis profile) | Details not disclosed |
5D. Discontinued / divested
| Brand | Description | Status |
|---|---|---|
| Elixinol (USA) | Elixinol-branded hemp/CBD nutraceuticals and skincare; brand refresh and new products prepared in 2025, rollout planned Q1 2026 | Sold to Ananda Health, Inc., completed 4 Sep 2026; EXL retains brand rights outside the US |
| Duplicate hemp brands | Rationalised in 2026 | Discontinued (Food & Drink Business, Sep 2026) |
5E. Pending — Vitable
| Feature | Detail |
|---|---|
| Offering | Personalised daily supplement packs via subscription, driven by an online health assessment |
| Scale | ~7,851 active subscribers; ~1.84 million health assessments/quiz records |
| Revenue | More than A$5 million annual revenue (company statement) |
| Founded | 2019, by Larah Loutati and Ilyas Anane |
| Funding history | A$5.5 million Series A (2021) backed by Brenteca Investments; a 2023 round; 2024 media-for-equity round with ScaleUp Mediafund |
| Status | Binding agreement 24 Sep 2026; subject to EXL shareholder approval at a meeting expected early November 2026 |
Sources: Business News Australia; StartupResearcher; EXL announcement 24 Sep 2026.
Financial Narrative
Basis: EXL consolidated, fiscal years ending 31 December, AUD millions. Primary source: S&P Global Market Intelligence data via StockAnalysis.com (standardised), cross-checked against company Appendix 4E releases. Company-defined Adjusted EBITDA shown separately. Note that FY2021–FY2023 figures pre-date or only partly include the TSN merger (implemented August 2023), the Ananda Food acquisition (2024) and The Healthy Chef (late 2024).
6A. Income statement: notes and sources
Sources: StockAnalysis (S&P Global) income statement; EXL Appendix 4E FY21 (loss A$17.025 million, EPS -5.41c, Adjusted EBITDA -A$11.5 million); FY22 Appendix 4E (loss A$10.571 million, Adjusted EBITDA -A$8.538 million); FY24 Appendix 4E (loss A$1.722 million); FY25 Appendix 4E (loss A$5.5 million, EPS -2.15c vs -1.11c). FY24 Adjusted EBITDA was originally reported as a A$2.8 million loss (28 Feb 2025) and restated to A$3.0 million in the FY25 release — a discrepancy noted. FY24 net loss benefited from a one-off A$3.6 million tax benefit.
6B. Margins (%)
Revenue CAGR FY2021–FY2025 (derived): ~13.5% per year (A$9.34 million to A$15.50 million), almost entirely acquisition-driven. Organic growth in FY25 was low single digits at group level (+3.6%), with Australia +8% offset by the US decline.
Sources conflict on gross margin: the company reports 38% (FY24) and 39% (FY25), while S&P standardisation shows 35.8% and 36.9%, likely reflecting differing classification of freight or inventory costs. Both are shown.
6C. Balance sheet: notes and sources
Source: S&P Global via StockAnalysis (share counts as reported by S&P; which may be adjusted for capital reconstructions; the FY22 count of 39.5 million is inconsistent with the scheme's 1.1225-for-1 issue to 120.6 million TSN shares unless a consolidation occurred). Short- and long-term debt splits derived by analyst from S&P line items. At 30 June 2026: cash A$1.0 million, total debt A$4.03 million, net debt A$3.04 million, equity A$6.36 million, working capital -A$1.55 million. Net tangible assets swung from +A$0.3 million to -A$1.5 million during FY25 (-0.36 cents per share) (FY25 Appendix 4E).
6D. Cash flow: notes and sources
Source: S&P Global via StockAnalysis cash-flow statement; capex derived as OCF minus FCF. Note FY23 "cash acquisitions" of +0.19 reflects cash acquired with TSN. Company-reported net cash used in operating activities was A$3.2 million in FY25 vs A$3.5 million in FY24 (FY25 release).
6E. Ratios
All ratios derived by the analyst from the S&P data above. Net debt/EBITDA is not meaningful because EBITDA is negative in every year.
6F. Commentary on trends, inflections and drivers
Revenue. EXL's revenue troughed in FY2022 at A$7.06 million as the legacy Elixinol CBD business contracted (FY2021 revenue fell 38% and FY2022 a further 24%). Growth since then has been bought rather than built: the TSN merger (August 2023) lifted FY2023, and the Ananda Food and Healthy Chef acquisitions drove the 81% jump in FY2024. FY2025 growth of 3.6% masked divergent drivers — Australian e-commerce rose 163% to A$4.3 million on a full year of The Healthy Chef and six new products, while Australian retail fell 19% to A$7.1 million on supermarket SKU rationalisation, and US revenue fell from A$2.1 million to A$1.6 million on CBD branding restrictions (FY25 release).
Gross margin. The structural mix shift is the single most important positive trend. Lower-margin bulk ingredients fell from 24% to 14% of revenue, e-commerce rose from 21% to 38%, and quarterly gross margin climbed from ~37% (Q1 FY25) to 42% (Q4 FY25) and 45% (Q1 and Q2 FY26) (Q1 and Q2 FY26 4Cs). Management attributes 1H FY25 margin pressure to legacy contracts and unprofitable SKUs hit by global ingredient pricing.
Operating costs. Operating expenses rose 8% in FY25 because of one-off integration and streamlining costs, but the Q4 FY25 cost base was 30% below Q4 FY24, and 1H FY26 operating expenses fell A$1.1 million (25%) to A$3.3 million. Adjusted EBITDA turned positive in Q4 FY25.
Net loss. The FY24 net loss of A$1.7 million flatters underlying performance because of a one-off A$3.6 million tax benefit (recognition of deferred tax assets, now A$3.79 million on balance sheet). The FY25 loss of A$5.5 million is closer to the true run-rate of that year. The 1H FY26 loss narrowed, with the most recent half-year net loss approximately A$1.07 million versus A$2.41 million in the preceding half (Investing.com summary of semi-annual data).
Cash and balance sheet. Cash burn has fallen from A$14 million (FY21) to ~A$3.2 million (FY25), and underlying operating cash flow (excluding finance costs, tax and non-recurring items) was positive for three consecutive quarters to June 2026. However, statutory operating cash flow remained negative (net operating outflow A$0.58 million in Q2 FY26 and A$0.14 million in Q1 FY26), cash fell to ~A$1.0 million by June 2026, working capital is negative, and debt has roughly doubled to ~A$4 million (largely loan notes, partly secured over the former US business). The balance sheet is the binding constraint on strategy.
6G. Historical TSN/APH standalone financials: notes and sources
Sources: Stockhead (H1 FY21 revenue A$0.74 million, loss A$1.05 million vs A$4.85 million pcp — the H1 FY20 loss includes reverse-takeover costs); Food & Drink Business (H1 FY22 revenue A$1.6 million, EBITDA approximately -A$2.8 million); TSN H1 FY23 Appendix 4D/interim report.
Source: TSN H1 FY23 interim report (statements of financial position and changes in equity). TSN's half-year accounts carried a going-concern material uncertainty (H1 FY23 auditor's review report).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products |
|---|---|---|
Australia | Hemp Foods Australia, Australian Primary Hemp, Mt Elephant, The Australian Superfood Co, Field Day, The Healthy Chef, Ananda Food / Ananda Equine, Soul Seeds/Soul Foods, contract manufacturing and bulk ingredients | Hemp seeds, oils, proteins; snack bars, pancakes, baking mixes; protein powders and protein waters; superfood ingredients; pet and equine products; bulk hemp |
Americas (discontinued Sep 2026) | Elixinol LLC (Broomfield, Colorado) | Elixinol-branded hemp/CBD nutraceuticals and skincare |
Rest of World | Elixinol BV, Elixinol Limited | Limited contribution; EXL retains the Elixinol brand outside the US |
Revenue by Segment
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Australia revenue (AUD Mn) | — | 12.9 | 13.9 |
Americas / USA revenue (AUD Mn) | — | 2.1 | 1.6 |
Group revenue (AUD Mn) | 8.27 | 14.96 | 15.50 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Segment metric | FY2024 | FY2025 |
|---|---|---|
Australia YoY growth (%) | — | 8 |
Americas YoY growth (%, derived) | — | -24 |
Australia share of group revenue (%, derived) | 86 | 90 |
Americas share of group revenue (%, derived) | 14 | 10 |
Brand / Period Metric Details
| Brand / period metric | Value | Source |
|---|---|---|
The Healthy Chef revenue, H1 FY25 | 1.7 | H1 FY25 results (29 Aug 2025) |
Hemp Foods Australia revenue, H1 FY25 | 2.4 | H1 FY25 results |
Elixinol USA revenue, H1 FY25 | 0.8 | H1 FY25 results |
Mt Elephant revenue, Q3 FY24 (quarter) | 0.411 (+60% YoY) | Q3 FY24 4C (22 Oct 2024) |
Hemp products revenue, 9 months to Sep 2026 | 6.4 | Grafa (13 Oct 2026) |
Continuing-operations revenue, H1 FY26 | 7.2 (+5.8%) | H1 FY26 Appendix 4D via Kalkine |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 9.34 | 7.06 | 8.27 | 14.96 | 15.50 |
Revenue growth (%) | -37.8 | -24.5 | 17.2 | 80.9 | 3.6 |
Cost of revenue (AUD Mn) | 7.22 | 4.07 | 5.00 | 9.60 | 9.79 |
Gross profit (AUD Mn) | 2.12 | 2.99 | 3.27 | 5.36 | 5.71 |
Operating expenses (AUD Mn) | 20.00 | 12.74 | 9.31 | 10.41 | 10.77 |
Operating income (AUD Mn) | -17.89 | -9.75 | -6.04 | -5.05 | -5.06 |
EBITDA, S&P basis (AUD Mn) | -17.40 | -9.57 | -5.92 | -4.51 | -4.41 |
Adjusted EBITDA, company basis (AUD Mn) | -11.50 | -8.54 | — | -3.00 | -3.40 |
Interest expense (AUD Mn) | 0.09 | 0.07 | 0.10 | 0.21 | 0.49 |
Net income attributable (AUD Mn) | -17.03 | -10.57 | -7.51 | -1.72 | -5.50 |
Basic EPS (AUD cents) | -5.41 | — | — | -1.11 | -2.15 |
Diluted EPS (AUD cents) | -5.41 | — | — | -1.11 | -2.15 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin, S&P basis (%) | 22.7 | 42.3 | 39.5 | 35.8 | 36.9 |
Gross margin, company basis (%) | — | — | — | 38 | 39 |
Operating margin (%) | -191.5 | -138.2 | -73.1 | -33.8 | -32.6 |
EBITDA margin, S&P basis (%) | -186.3 | -135.7 | -71.6 | -30.2 | -28.4 |
Net margin (%) | -182.3 | -149.8 | -90.8 | -11.5 | -35.5 |
Balance Sheet and Share Count (M)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | 25.33 | 13.49 | 11.71 | 18.45 | 15.96 |
Cash and equivalents (AUD Mn) | 12.65 | 2.86 | 0.71 | 1.08 | 1.41 |
Inventory (AUD Mn) | 2.20 | 1.74 | 3.66 | 3.89 | 2.66 |
Short-term debt incl. current leases (AUD Mn) | 1.18 | 1.02 | 1.08 | 1.30 | 3.41 |
Long-term debt incl. leases (AUD Mn) | 1.54 | 0.89 | 0.19 | 0.64 | 0.32 |
Total debt (AUD Mn) | 2.72 | 1.90 | 1.26 | 1.94 | 3.73 |
Net debt (AUD Mn, negative = net cash) | -9.93 | -0.96 | 0.55 | 0.86 | 2.32 |
Total equity (AUD Mn) | 19.08 | 9.16 | 6.46 | 10.03 | 7.45 |
Goodwill and intangibles (AUD Mn) | 0.46 | 0.15 | 2.30 | 6.18 | 5.15 |
Deferred tax assets (AUD Mn) | 0 | 0 | 0 | 3.59 | 3.79 |
Working capital (AUD Mn) | 14.87 | 5.87 | 3.19 | 2.19 | -0.94 |
Shares outstanding (M) | 39.47 | 39.52 | 79.09 | 220.82 | 413.99 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | -14.07 | -8.15 | -2.76 | -3.47 | -3.21 |
Capital expenditure (AUD Mn, derived) | 0.16 | 0.01 | 0.01 | 0.06 | 0.07 |
Free cash flow (AUD Mn) | -14.23 | -8.16 | -2.77 | -3.53 | -3.28 |
Cash acquisitions (AUD Mn) | 0 | 0 | -0.19 | 2.27 | 0.12 |
Financing cash flow (AUD Mn) | -1.16 | -0.76 | 1.61 | 3.92 | 3.65 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE on year-end equity (%) | -89.3 | -115.4 | -116.3 | -17.1 | -73.8 |
ROA on year-end assets (%) | -67.2 | -78.4 | -64.1 | -9.3 | -34.5 |
ROIC proxy: EBIT / (equity + debt) (%) | -82.1 | -88.1 | -78.2 | -42.2 | -45.3 |
Current ratio (x) | 4.15 | 2.71 | 1.64 | 1.44 | 0.86 |
Debt to equity (x) | 0.14 | 0.21 | 0.20 | 0.19 | 0.50 |
Interest coverage: EBIT / interest (x) | -198.8 | -139.3 | -60.4 | -24.0 | -10.3 |
Asset turnover: revenue / year-end assets (x) | 0.37 | 0.52 | 0.71 | 0.81 | 0.97 |
Inventory days (derived) | 111 | 156 | 267 | 148 | 99 |
Receivable days (derived) | 25 | 37 | 69 | 32 | 25 |
Payable days (derived) | 69 | 97 | 128 | 69 | 57 |
Cash conversion cycle, days (derived) | 67 | 96 | 208 | 111 | 67 |
Cash Flow and Margin Analysis (%)
| Metric | H1 FY2020 | H1 FY2021 | H1 FY2022 | H1 FY2023 |
|---|---|---|---|---|
Revenue (AUD Mn) | — | 0.74 | 1.60 | 1.86 |
Revenue growth vs pcp (%) | — | 51.8 | 103.6 | 15.9 |
Net loss after tax (AUD Mn) | -4.85 | -1.05 | -2.78 | -1.68 |
Basic EPS (AUD cents) | — | — | -2.84 | -1.40 |
Operating cash flow (AUD Mn) | — | — | -2.89 | -0.82 |
Employee benefits expense (AUD Mn) | — | — | 1.56 | 1.08 |
Marketing expense (AUD Mn) | — | — | 0.77 | 0.12 |
Balance Sheet
| TSN balance sheet metric | 30 Jun 2021 | 30 Jun 2022 | 31 Dec 2022 |
|---|---|---|---|
Cash (AUD Mn) | 4.10 | 0.38 | 0.51 |
Inventories (AUD Mn) | — | 3.26 | 3.28 |
Total assets (AUD Mn) | — | 7.43 | 7.11 |
Borrowings, current + non-current (AUD Mn) | — | 1.02 | 2.12 |
Total equity (AUD Mn) | 5.31 | 4.90 | 3.36 |
Working capital (AUD Mn) | — | 2.90 | 1.52 |
Accumulated losses (AUD Mn) | -13.54 | -18.78 | -20.24 |
Revenue by Region
| Region | FY2024 | FY2025 |
|---|---|---|
Australia revenue (AUD Mn) | 12.9 | 13.9 |
USA revenue (AUD Mn) | 2.1 | 1.6 |
Region growth
| Region growth | FY2025 |
|---|---|
Australia YoY growth (%) | 8 |
USA YoY growth (%, derived) | -24 |
Revenue by Region by Australia Channel
| Australia channel | FY2024 | FY2025 |
|---|---|---|
E-commerce (AUD Mn) | 1.6 | 4.3 |
Retail (AUD Mn) | 8.8 | 7.1 |
Other incl. bulk / contract (AUD Mn, derived residual) | 2.5 | 2.5 |
Share Price History
| Date | Price (AUD) | Note | Source |
|---|---|---|---|
21 Apr 2026 | 0.008 | +14.3% on Q1 FY26 update | Kalkine |
31 Jul 2026 | 0.007 | +16.7% intraday | StockAnalysis |
13 Oct 2026 | 0.006 | -14.3% on day | Kalkine |
16 Oct 2026 | 0.007 | Latest close | StockAnalysis |
Valuation Multiples
| Multiple | EXL | Basis |
|---|---|---|
Market cap (AUD Mn) | ~2.9 | 413.99 million shares × A$0.007 |
Enterprise value (AUD Mn, derived) | ~5.9 | Market cap + net debt A$3.04 million (Jun 2026) |
EV / Sales, TTM (x, derived) | ~0.37 | TTM revenue A$15.9 million |
P/B (x, derived) | ~0.46 | Equity A$6.36 million (Jun 2026) |
Capital Markets
| Item | Status |
|---|---|
Sell-side consensus | None identified; no price targets |
Dividend history | No dividends paid or declared in FY2024 or FY2025, nor by TSN historically |
Buyback authorisation | None (TSN confirmed no on-market buyback, Dec 2022) |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | ~A$3.4 million of debt current at Dec 2025 (incl. current portion of long-term debt A$1.82 million and short-term debt A$1.44 million); loan notes rolled over in 2026; up to A$2 million convertible notes sought; A$500,000 Vitable-related convertible note. |
Raise by Date
| Date | Raise | Amount (AUD Mn) |
|---|---|---|
Jul–Dec 2021 (TSN) | Placement | 4.70 |
Feb–Apr 2024 | Capital raise for Ananda Food | 3.16 |
Oct 2024 | Placement + SPP for Healthy Chef | 1.1 + up to 0.5 |
1H 2025 | Debt and equity | 1.5 |
2H 2025 | Two-tranche raise | 2.5 |
Sep 2026 | Convertible note (Vitable-related) | 0.5 |
Analyst Conclusions
22A. Management guidance
No formal numerical earnings guidance has been issued for FY26. Management priorities for 2H FY26 are sustaining the underlying operating cash-flow improvement and growing through new retail distribution (Priceline, Coles-focused Mt Elephant, Costco relaunch), product launches and additional B2B contracts. Post-Vitable, the company targets more than A$20 million annualised revenue at completion and ~A$27 million revenue with ~A$3 million EBITDA by 2028 on full earn-out realisation; an illustrative A$50 million revenue ambition over three to five years is explicitly not guidance.
22B. Consensus
No broker consensus exists. TTM revenue to June 2026 was A$15.9 million (+6.1% YoY, StockAnalysis).
22C. Bull case
-
Margin-led turnaround is real: gross margin up eight points year-on-year to 45%, opex down 25%, and three straight quarters of positive underlying operating cash flow suggest the business can self-fund at current scale.
-
Vitable is cheap, structured, aligned: A$2.5 million headline scrip for more than A$5 million of recurring revenue (~0.5x sales) with most upside consideration contingent on market-cap and performance hurdles; cross-sell into a high-margin Healthy Chef range could lift group margins further.
-
Option value at a tiny valuation: at ~0.37x EV/sales, the market prices in failure; delivery of the 2028 targets (~A$3 million EBITDA) would imply a multiple of today's ~A$6 million enterprise value.
22D. Bear case
-
Balance sheet is too thin: ~A$1.0 million cash, ~A$4 million debt and negative working capital leave little margin for error; any trading setback forces another sub-cent raise.
-
Dilution overwhelms value creation: up to 666.7 million deferred Vitable shares on a 414 million base, plus convertible notes, mean per-share value may lag business improvement even if the strategy works.
-
Track record of misses: the FY25 EBITDA break-even target was missed, both legacy companies (Elixinol Global and TSN) lost cumulatively large sums, and branded grocery positions (Mt Elephant) have repeatedly been delisted.
22E. Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing |
|---|---|
| Notice of General Meeting and EGM vote on Vitable; ASX waiver outcome | Oct–Nov 2026 (approval date 27 Nov 2026) |
| Vitable completion; issue of deferred consideration shares | Proposed 7 Dec 2026 |
| Q3 FY26 4C (quarter to Sep 2026) | Late Oct 2026 |
| Hemp Gold Protein Costco relaunch | Q4 2026 |
| FY26 full-year results (first Australia-only year) | Late Feb 2027 |
| Statutory (not just "underlying") operating cash-flow break-even | Each quarterly 4C |
| Convertible note terms and loan-note maturities | Ongoing |
| Priceline stage-two rollout and Mt Elephant Coles innovation | 2,027 |
| Further M&A announcements | Ongoing |
22F. Analyst verdict
The Sustainable Nutrition Group no longer exists as an investable security. Its listed history — a failed biotech shell reborn as Australian Primary Hemp in 2019, renamed in 2021 and absorbed by Elixinol Wellness for scrip worth about three cents a share in 2023 — destroyed most of the capital raised along the way. Exposure to the APH, Mt Elephant, Superfood Co and Field Day businesses today is available only through Elixinol Wellness (ASX: EXL).
EXL itself is a classic micro-cap turnaround with genuine but early evidence of operational progress. The improvements are not cosmetic: gross margin has risen from the mid-30s to 45%, the cost base has been cut by roughly a quarter to a third, unprofitable US operations have been sold, and underlying operating cash flow has been positive for three consecutive quarters. Management has also concentrated resources on its one clearly advantaged asset, The Healthy Chef, and secured hemp ingredient volume through 2027.
The problem is the capital structure. With roughly A$1 million of cash, around A$4 million of debt, negative working capital and negative tangible equity, the company has almost no buffer, and its growth strategy depends on paying for acquisitions in shares priced below one cent. The Vitable transaction is strategically coherent and attractively structured on an enterprise basis, but the potential issue of up to 666.7 million deferred shares illustrates how readily per-share value can be diluted even when the business improves.
On balance, EXL should be regarded as a high-risk, speculative position. The equity offers asymmetric upside if statutory cash-flow break-even is reached and Vitable delivers its earn-out targets, but the base case is continued dilution. Key evidence to watch is whether statutory — not merely underlying — operating cash flow turns positive in the first half of 2027.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background |
|---|---|---|---|
Gavin Evans | Independent Non-Executive Chair | Since Dec 2025 | Founder of OpenWay Food Co., a vertically integrated portfolio of better-for-you brands (Red Tractor, Table of Plenty, Keep It Cleaner); board roles across FMCG, resources, fintech and not-for-profit; M&A experience |
Natalie Butler | CEO & Executive Director | — | Commercial and operational experience in consumer health (per Chair) |
Adam Dimitropoulos | Chief Financial Officer | — | — |
Katie Mackenzie | Investor Relations | Current | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
| 2024 | Ron Dufficy serving as CEO & MD; David Fenton as Chair | Led Ananda Food and Healthy Chef acquisitions |
| 2025 | Leadership team rebuilt: Natalie Butler (CEO & ED), Adam Dimitropoulos (CFO) | Post-integration reset |
Dec 2025 | Gavin Evans appointed Chair | Described by Evans as a pivotal moment for the company |
Earlier (Elixinol Global era) | Founder Paul Benhaim as Chair; CEO changes including Stratos Karousos and Oliver Horn (ex-Swisse) | Elixinol Global's CBD-focused era (Hemp Industry Daily) |
Board of Directors
| Name | Role |
|---|---|
Pauline Gately | Non-Executive Chair and Interim Executive Chair |
James Hood | Non-Executive Director |
Shane Gild | Independent Non-Executive Director |
Thomas Siebel | Independent Non-Executive Director |
Melanie Leydin | Company Secretary |
Neale Joseph | Former MD & CEO (resigned mid-2022) |
Karun Moses | COO (stepped up after CEO departure) |
Cameron Petricevic | Only Alchemia director retained post-RTO (2019) |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Relative positioning |
|---|---|---|---|
Hemp foods / ingredients | Ecofibre Ltd (ASX: EOF) — formerly owned Ananda Food; owns Ananda Health (US) | Listed | Larger diversified group (FY24 revenue ~A$28.0 million) but heavily loss-making; exited Australian hemp food by selling to EXL |
Hemp foods | Essential Hemp, Hemp Farms Australia and other independent domestic processors | Private | Fragmented smaller rivals; EXL claims a leading Australian hemp-foods supply position |
Hemp foods | Imported hemp seed products (e.g., Canadian suppliers) | Private/foreign | Price competition; APH's founding thesis was displacing imports |
Plant-based milks | Noumi Ltd (ASX: NOU) — MILKLAB, Australia's Own | Listed | FY26 revenue A$648.4 million; plant-based milk revenue A$186.3 million; far larger scale |
Plant-based milks | Sanitarium (So Good), Vitasoy, Oatly | Private / foreign listed | Dominant brands that crowded out Mt Elephant Mylk |
Protein / wellness powders | Musashi, Macro Mike, Nutra Organics, Bulk Nutrients, private-label | Private | Compete with The Healthy Chef in e-commerce and pharmacy |
Vitamins and supplements | Swisse (H&H Group), Blackmores (Kirin), Nature's Way, Life-Space (Asahi) | Multinational subsidiaries | Dominant in pharmacy; context for Vitable |
Personalised supplements / DTC health | Eucalyptus (being acquired by Hims & Hers), Persona Nutrition (Nestlé), Thorne (P&G) | Global | Validate category; vastly better capitalised |
Better-for-you snacks | Carman's, Table of Plenty (OpenWay), Blue Dinosaur, supermarket private label | Private | Compete with Mt Elephant for shrinking grocery shelf space |
Superfood ingredients | Bulk ingredient traders and importers | Private | Commodity pricing pressure |
Peer Comparison FY2025
| Metric | EXL (FY Dec 2025) | Noumi (FY Jun 2026) | Ecofibre (FY Jun 2024) |
|---|---|---|---|
Revenue (AUD Mn) | 15.5 | 648.4 | 28.0 |
Revenue growth (%) | 3.6 | 8.8 | -13.9 |
Gross margin (%) | 39 | — | — |
Adjusted EBITDA (AUD Mn) | -3.4 | 61.8 | — |
Net profit after tax (AUD Mn) | -5.5 | -67.2 | -39.2 |



